Cargando…
A Prediction Model to Prioritize Individuals for a SARS-CoV-2 Test Built from National Symptom Surveys
BACKGROUND: The gold standard for COVID-19 diagnosis is detection of viral RNA through PCR. Due to global limitations in testing capacity, effective prioritization of individuals for testing is essential. METHODS: We devised a model estimating the probability of an individual to test positive for CO...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7547576/ https://www.ncbi.nlm.nih.gov/pubmed/33073258 http://dx.doi.org/10.1016/j.medj.2020.10.002 |
_version_ | 1783592449323565056 |
---|---|
author | Shoer, Saar Karady, Tal Keshet, Ayya Shilo, Smadar Rossman, Hagai Gavrieli, Amir Meir, Tomer Lavon, Amit Kolobkov, Dmitry Kalka, Iris Godneva, Anastasia Cohen, Ori Kariv, Adam Hoch, Ori Zer-Aviv, Mushon Castel, Noam Sudre, Carole Zohar, Anat Ekka Irony, Angela Spector, Tim Geiger, Benjamin Hizi, Dorit Shalev, Varda Balicer, Ran Segal, Eran |
author_facet | Shoer, Saar Karady, Tal Keshet, Ayya Shilo, Smadar Rossman, Hagai Gavrieli, Amir Meir, Tomer Lavon, Amit Kolobkov, Dmitry Kalka, Iris Godneva, Anastasia Cohen, Ori Kariv, Adam Hoch, Ori Zer-Aviv, Mushon Castel, Noam Sudre, Carole Zohar, Anat Ekka Irony, Angela Spector, Tim Geiger, Benjamin Hizi, Dorit Shalev, Varda Balicer, Ran Segal, Eran |
author_sort | Shoer, Saar |
collection | PubMed |
description | BACKGROUND: The gold standard for COVID-19 diagnosis is detection of viral RNA through PCR. Due to global limitations in testing capacity, effective prioritization of individuals for testing is essential. METHODS: We devised a model estimating the probability of an individual to test positive for COVID-19 based on answers to 9 simple questions that have been associated with SARS-CoV-2 infection. Our model was devised from a subsample of a national symptom survey that was answered over 2 million times in Israel in its first 2 months and a targeted survey distributed to all residents of several cities in Israel. Overall, 43,752 adults were included, from which 498 self-reported as being COVID-19 positive. FINDINGS: Our model was validated on a held-out set of individuals from Israel where it achieved an auROC of 0.737 (CI: 0.712–0.759) and auPR of 0.144 (CI: 0.119–0.177) and demonstrated its applicability outside of Israel in an independently collected symptom survey dataset from the US, UK, and Sweden. Our analyses revealed interactions between several symptoms and age, suggesting variation in the clinical manifestation of the disease in different age groups. CONCLUSIONS: Our tool can be used online and without exposure to suspected patients, thus suggesting worldwide utility in combating COVID-19 by better directing the limited testing resources through prioritization of individuals for testing, thereby increasing the rate at which positive individuals can be identified. Moreover, individuals at high risk for a positive test result can be isolated prior to testing. FUNDING: E.S. is supported by the Crown Human Genome Center, Larson Charitable Foundation New Scientist Fund, Else Kroener Fresenius Foundation, White Rose International Foundation, Ben B. and Joyce E. Eisenberg Foundation, Nissenbaum Family, Marcos Pinheiro de Andrade and Vanessa Buchheim, Lady Michelle Michels, and Aliza Moussaieff and grants funded by the Minerva foundation with funding from the Federal German Ministry for Education and Research and by the European Research Council and the Israel Science Foundation. H.R. is supported by the Israeli Council for Higher Education (CHE) via the Weizmann Data Science Research Center and by a research grant from Madame Olga Klein – Astrachan. |
format | Online Article Text |
id | pubmed-7547576 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-75475762020-10-13 A Prediction Model to Prioritize Individuals for a SARS-CoV-2 Test Built from National Symptom Surveys Shoer, Saar Karady, Tal Keshet, Ayya Shilo, Smadar Rossman, Hagai Gavrieli, Amir Meir, Tomer Lavon, Amit Kolobkov, Dmitry Kalka, Iris Godneva, Anastasia Cohen, Ori Kariv, Adam Hoch, Ori Zer-Aviv, Mushon Castel, Noam Sudre, Carole Zohar, Anat Ekka Irony, Angela Spector, Tim Geiger, Benjamin Hizi, Dorit Shalev, Varda Balicer, Ran Segal, Eran Med (N Y) Clinical and Translational Resource and Technology Insights BACKGROUND: The gold standard for COVID-19 diagnosis is detection of viral RNA through PCR. Due to global limitations in testing capacity, effective prioritization of individuals for testing is essential. METHODS: We devised a model estimating the probability of an individual to test positive for COVID-19 based on answers to 9 simple questions that have been associated with SARS-CoV-2 infection. Our model was devised from a subsample of a national symptom survey that was answered over 2 million times in Israel in its first 2 months and a targeted survey distributed to all residents of several cities in Israel. Overall, 43,752 adults were included, from which 498 self-reported as being COVID-19 positive. FINDINGS: Our model was validated on a held-out set of individuals from Israel where it achieved an auROC of 0.737 (CI: 0.712–0.759) and auPR of 0.144 (CI: 0.119–0.177) and demonstrated its applicability outside of Israel in an independently collected symptom survey dataset from the US, UK, and Sweden. Our analyses revealed interactions between several symptoms and age, suggesting variation in the clinical manifestation of the disease in different age groups. CONCLUSIONS: Our tool can be used online and without exposure to suspected patients, thus suggesting worldwide utility in combating COVID-19 by better directing the limited testing resources through prioritization of individuals for testing, thereby increasing the rate at which positive individuals can be identified. Moreover, individuals at high risk for a positive test result can be isolated prior to testing. FUNDING: E.S. is supported by the Crown Human Genome Center, Larson Charitable Foundation New Scientist Fund, Else Kroener Fresenius Foundation, White Rose International Foundation, Ben B. and Joyce E. Eisenberg Foundation, Nissenbaum Family, Marcos Pinheiro de Andrade and Vanessa Buchheim, Lady Michelle Michels, and Aliza Moussaieff and grants funded by the Minerva foundation with funding from the Federal German Ministry for Education and Research and by the European Research Council and the Israel Science Foundation. H.R. is supported by the Israeli Council for Higher Education (CHE) via the Weizmann Data Science Research Center and by a research grant from Madame Olga Klein – Astrachan. Elsevier Inc. 2021-02-12 2020-10-10 /pmc/articles/PMC7547576/ /pubmed/33073258 http://dx.doi.org/10.1016/j.medj.2020.10.002 Text en © 2020 Elsevier Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Clinical and Translational Resource and Technology Insights Shoer, Saar Karady, Tal Keshet, Ayya Shilo, Smadar Rossman, Hagai Gavrieli, Amir Meir, Tomer Lavon, Amit Kolobkov, Dmitry Kalka, Iris Godneva, Anastasia Cohen, Ori Kariv, Adam Hoch, Ori Zer-Aviv, Mushon Castel, Noam Sudre, Carole Zohar, Anat Ekka Irony, Angela Spector, Tim Geiger, Benjamin Hizi, Dorit Shalev, Varda Balicer, Ran Segal, Eran A Prediction Model to Prioritize Individuals for a SARS-CoV-2 Test Built from National Symptom Surveys |
title | A Prediction Model to Prioritize Individuals for a SARS-CoV-2 Test Built from National Symptom Surveys |
title_full | A Prediction Model to Prioritize Individuals for a SARS-CoV-2 Test Built from National Symptom Surveys |
title_fullStr | A Prediction Model to Prioritize Individuals for a SARS-CoV-2 Test Built from National Symptom Surveys |
title_full_unstemmed | A Prediction Model to Prioritize Individuals for a SARS-CoV-2 Test Built from National Symptom Surveys |
title_short | A Prediction Model to Prioritize Individuals for a SARS-CoV-2 Test Built from National Symptom Surveys |
title_sort | prediction model to prioritize individuals for a sars-cov-2 test built from national symptom surveys |
topic | Clinical and Translational Resource and Technology Insights |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7547576/ https://www.ncbi.nlm.nih.gov/pubmed/33073258 http://dx.doi.org/10.1016/j.medj.2020.10.002 |
work_keys_str_mv | AT shoersaar apredictionmodeltoprioritizeindividualsforasarscov2testbuiltfromnationalsymptomsurveys AT karadytal apredictionmodeltoprioritizeindividualsforasarscov2testbuiltfromnationalsymptomsurveys AT keshetayya apredictionmodeltoprioritizeindividualsforasarscov2testbuiltfromnationalsymptomsurveys AT shilosmadar apredictionmodeltoprioritizeindividualsforasarscov2testbuiltfromnationalsymptomsurveys AT rossmanhagai apredictionmodeltoprioritizeindividualsforasarscov2testbuiltfromnationalsymptomsurveys AT gavrieliamir apredictionmodeltoprioritizeindividualsforasarscov2testbuiltfromnationalsymptomsurveys AT meirtomer apredictionmodeltoprioritizeindividualsforasarscov2testbuiltfromnationalsymptomsurveys AT lavonamit apredictionmodeltoprioritizeindividualsforasarscov2testbuiltfromnationalsymptomsurveys AT kolobkovdmitry apredictionmodeltoprioritizeindividualsforasarscov2testbuiltfromnationalsymptomsurveys AT kalkairis apredictionmodeltoprioritizeindividualsforasarscov2testbuiltfromnationalsymptomsurveys AT godnevaanastasia apredictionmodeltoprioritizeindividualsforasarscov2testbuiltfromnationalsymptomsurveys AT cohenori apredictionmodeltoprioritizeindividualsforasarscov2testbuiltfromnationalsymptomsurveys AT karivadam apredictionmodeltoprioritizeindividualsforasarscov2testbuiltfromnationalsymptomsurveys AT hochori apredictionmodeltoprioritizeindividualsforasarscov2testbuiltfromnationalsymptomsurveys AT zeravivmushon apredictionmodeltoprioritizeindividualsforasarscov2testbuiltfromnationalsymptomsurveys AT castelnoam apredictionmodeltoprioritizeindividualsforasarscov2testbuiltfromnationalsymptomsurveys AT sudrecarole apredictionmodeltoprioritizeindividualsforasarscov2testbuiltfromnationalsymptomsurveys AT zoharanatekka apredictionmodeltoprioritizeindividualsforasarscov2testbuiltfromnationalsymptomsurveys AT ironyangela apredictionmodeltoprioritizeindividualsforasarscov2testbuiltfromnationalsymptomsurveys AT spectortim apredictionmodeltoprioritizeindividualsforasarscov2testbuiltfromnationalsymptomsurveys AT geigerbenjamin apredictionmodeltoprioritizeindividualsforasarscov2testbuiltfromnationalsymptomsurveys AT hizidorit apredictionmodeltoprioritizeindividualsforasarscov2testbuiltfromnationalsymptomsurveys AT shalevvarda apredictionmodeltoprioritizeindividualsforasarscov2testbuiltfromnationalsymptomsurveys AT balicerran apredictionmodeltoprioritizeindividualsforasarscov2testbuiltfromnationalsymptomsurveys AT segaleran apredictionmodeltoprioritizeindividualsforasarscov2testbuiltfromnationalsymptomsurveys AT shoersaar predictionmodeltoprioritizeindividualsforasarscov2testbuiltfromnationalsymptomsurveys AT karadytal predictionmodeltoprioritizeindividualsforasarscov2testbuiltfromnationalsymptomsurveys AT keshetayya predictionmodeltoprioritizeindividualsforasarscov2testbuiltfromnationalsymptomsurveys AT shilosmadar predictionmodeltoprioritizeindividualsforasarscov2testbuiltfromnationalsymptomsurveys AT rossmanhagai predictionmodeltoprioritizeindividualsforasarscov2testbuiltfromnationalsymptomsurveys AT gavrieliamir predictionmodeltoprioritizeindividualsforasarscov2testbuiltfromnationalsymptomsurveys AT meirtomer predictionmodeltoprioritizeindividualsforasarscov2testbuiltfromnationalsymptomsurveys AT lavonamit predictionmodeltoprioritizeindividualsforasarscov2testbuiltfromnationalsymptomsurveys AT kolobkovdmitry predictionmodeltoprioritizeindividualsforasarscov2testbuiltfromnationalsymptomsurveys AT kalkairis predictionmodeltoprioritizeindividualsforasarscov2testbuiltfromnationalsymptomsurveys AT godnevaanastasia predictionmodeltoprioritizeindividualsforasarscov2testbuiltfromnationalsymptomsurveys AT cohenori predictionmodeltoprioritizeindividualsforasarscov2testbuiltfromnationalsymptomsurveys AT karivadam predictionmodeltoprioritizeindividualsforasarscov2testbuiltfromnationalsymptomsurveys AT hochori predictionmodeltoprioritizeindividualsforasarscov2testbuiltfromnationalsymptomsurveys AT zeravivmushon predictionmodeltoprioritizeindividualsforasarscov2testbuiltfromnationalsymptomsurveys AT castelnoam predictionmodeltoprioritizeindividualsforasarscov2testbuiltfromnationalsymptomsurveys AT sudrecarole predictionmodeltoprioritizeindividualsforasarscov2testbuiltfromnationalsymptomsurveys AT zoharanatekka predictionmodeltoprioritizeindividualsforasarscov2testbuiltfromnationalsymptomsurveys AT ironyangela predictionmodeltoprioritizeindividualsforasarscov2testbuiltfromnationalsymptomsurveys AT spectortim predictionmodeltoprioritizeindividualsforasarscov2testbuiltfromnationalsymptomsurveys AT geigerbenjamin predictionmodeltoprioritizeindividualsforasarscov2testbuiltfromnationalsymptomsurveys AT hizidorit predictionmodeltoprioritizeindividualsforasarscov2testbuiltfromnationalsymptomsurveys AT shalevvarda predictionmodeltoprioritizeindividualsforasarscov2testbuiltfromnationalsymptomsurveys AT balicerran predictionmodeltoprioritizeindividualsforasarscov2testbuiltfromnationalsymptomsurveys AT segaleran predictionmodeltoprioritizeindividualsforasarscov2testbuiltfromnationalsymptomsurveys |